Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting
Rhea-AI Summary
Rapport Therapeutics (Nasdaq: RAPP) will present new Phase 2a follow-up data for RAP-219 in focal onset seizures at the 2026 American Academy of Neurology Annual Meeting in Chicago.
The podium presentation covers 8-week follow-up efficacy and tolerability results for RAP-219 and is scheduled for April 21, 2026 at 3:54 PM CDT, presented by William W. Motley, M.D.
Positive
- None.
Negative
- None.
News Market Reaction – RAPP
In the Apr 1 session, RAPP gained 1.21%, reflecting a mild positive market reaction. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Clinical trial Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 07 | Phase 3 initiation | Positive | +8.9% | Accelerated start of RAP‑219 Phase 3 FOS program and broader pipeline updates. |
| Sep 08 | Phase 2a topline | Positive | +119.2% | Positive Phase 2a results in FOS with strong seizure reduction and seizure freedom rates. |
| Sep 05 | Data announcement date | Neutral | +119.2% | Scheduled announcement and call details for upcoming RAP‑219 Phase 2a topline results. |
| Jan 09 | Phase 1 data update | Positive | -11.3% | New Phase 1 data supporting receptor occupancy, tolerability, and CNS targeting for RAP‑219. |
| Jan 09 | Phase 1 data | Positive | -11.3% | Positive Phase 1 safety and PK results backing dosing for ongoing Phase 2a focal epilepsy trial. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Clinical trial news for RAP-219 has often driven large moves, with some strong rallies on positive efficacy data but also notable selloffs even on favorable Phase 1 updates.
Over the past year, Rapport’s clinical trial updates on RAP‑219 have ranged from early Phase 1 data to positive Phase 2a topline results and preparation for Phase 3 FOS trials. Major catalysts included a proof‑of‑concept Phase 2a readout with strong seizure reduction and an accelerated Phase 3 initiation decision. Earlier Phase 1 updates in January 2025 coincided with share price declines despite generally favorable safety and pharmacodynamic data, highlighting that market reactions to clinical progress have not always been uniformly positive.
Key Terms
phase 2a medical
focal onset seizures medical
negative allosteric modulator medical
ampa receptor medical
scientific platform session technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON and SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that it will present results from its Phase 2a trial of RAP-219 in patients with focal onset seizures (FOS), including new data from the 8-week follow-up period, in a podium presentation at the upcoming 2026 American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22 in Chicago.
Presentation Details
- Title: Efficacy and Tolerability of RAP-219, a Potential First-in-Class Negative Allosteric Modulator of γ8 Transmembrane AMPA Receptor Regulatory Protein: Impact on RNS Long Episodes and Clinical Seizures
- Presenter: William W. Motley, M.D., RAP-219 Program Leader at Rapport Therapeutics
- Session Type: Scientific Platform Session
- Date & Time: April 21, 2026 at 3:54 PM CDT/4:54 PM EDT
Additional information about the 2026 AAN Annual Meeting is available at www.aan.com.
About RAP-219
RAP-219 is a potential first-in-class, clinical-stage TARPγ8-specific AMPA receptor (AMPAR) negative allosteric modulator (NAM). Whereas AMPARs are distributed widely in the central nervous system, the receptor associated protein (RAP) TARPγ8 is expressed only in discrete brain regions, including the hippocampus and neocortex, where focal seizures often originate. By contrast, TARPγ8 has minimal expression in the hindbrain, where drug effects are often associated with intolerable adverse events. With this precision approach, the Company believes RAP-219 has the potential to provide a differentiated profile as compared to traditional neuroscience medications. Due to the role of AMPA biology in various neurological disorders and the selective targeting of TARPγ8, the Company believes RAP-219 has pipeline-in-a-product potential and is evaluating the compound as a potential treatment for patients with focal onset seizures, primary generalized tonic-clonic seizures, bipolar disorder, and peripheral neuropathic pain.
About Rapport Therapeutics
Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients with neurological and psychiatric disorders. The Company’s founders made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain, which form the basis of Rapport’s RAP technology platform. The platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport’s precision neuroscience pipeline is anchored by its epilepsy portfolio, including focal onset seizures and primary generalized tonic-clonic seizures, in addition to bipolar mania. The Company is also advancing additional discovery and preclinical programs leveraging its platform, including in chronic pain and migraine and in hearing and vestibular disorders.
Availability of Other Information About Rapport Therapeutics
Rapport Therapeutics uses and intends to continue to use its Investor Relations website and LinkedIn (Rapport Therapeutics) as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Company’s Investor Relations website and LinkedIn, in addition to following the Company’s press releases, SEC filings, public conference calls, presentations, and webcasts. The contents of the Company’s website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Contact
Julie DiCarlo
Head of Communications & IR
Rapport Therapeutics
jdicarlo@rapportrx.com
